Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00491686 · ClinicalTrials.gov registry record · Phase 2
AZD6765 for Treatment Resistant Depression
A Phase 2 study of Depression, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
- 5
- Study locations
NCT00491686 is a Phase 2 study of Depression that has completed, run by AstraZeneca. The registered enrollment target is 34 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (96% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT00491686, a Phase 2 study of Depression, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to determine whether treatment with AZD6765 will have an antidepressant effect with patients who have treatment resistant depression.
Conditions Studied
Interventions
- DRUG AZD6765
Study Locations (5)
Connecticut
- Research Site - Hartford
- Research Site - New Haven
California
- Research Site - Glendale
Kansas
- Research Site - Wichita
Maryland
- Research Site - Rockville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2007-07 |
| Est. Completion | 2007-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00491686
The ClinicalTrials.gov registry entry for NCT00491686 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (96% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 1 intervention - of which AZD6765 is the first listed.
NCT00491686 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Connecticut, California, Kansas.
Frequently Asked Questions
What is clinical trial NCT00491686 about?
NCT00491686 is a clinical study titled "AZD6765 for Treatment Resistant Depression". The purpose of this study is to determine whether treatment with AZD6765 will have an antidepressant effect with patients who have treatment resistant depression.
What is the current status of trial NCT00491686?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2007-07. Estimated completion is 2007-11.
What conditions does trial NCT00491686 study?
This clinical trial studies the following conditions: Depression.
What interventions are being tested in trial NCT00491686?
The interventions under investigation include: AZD6765 (DRUG).
Who is sponsoring clinical trial NCT00491686?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00491686 being conducted?
This trial has 5 study locations across California, Connecticut, Kansas, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
-
Resources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
Cannabidiol and Older Adult Cannabis Users
RECRUITING · Phase 2
-
Evaluation of a Keto-Like Supplement on Brain Responses to Emotional Stimuli in Depression
RECRUITING · Phase 2
-
Neurobiology of Suicide
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.